NCE-1 Intelligence & Market Opportunity

Wayrilz

Rilzabrutinib

Immunomodulators

Oral Tablet

Wayrilz is an oral reversible BTK inhibitor indicated for adults with chronic immune thrombocytopenia (ITP). It works by modulating immune pathways to increase platelet counts and reduce the risk of bleeding, offering a convenient twice-daily oral treatment option.

Approval Date

29-Aug-25

NCE-1 Date

29-Aug-29

NCE Date

29-Aug-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

171.24%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

102

2027

203

2028

326

2029

433

2030

582

2031

715

2032

836

Molecule profile

Details & specifications

Molecule

Rilzabrutinib

Innovator

GENZYME CORP

Dosage Form

Oral Tablet

Strength

400 mg

Therapeutic Category

Immunomodulators

Usage

To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets